MC-Val-Cit-PAB
|
|
- CAS-Nr.
- 159857-80-4
- Englisch Name:
- MC-Val-Cit-PAB
- Synonyma:
- N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide;6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide;MC-Val-Cit-PAB-OH;EOS-60616;MC-Val-it-PAB;ML-Val-Cit-PAB;MC-Val-Cit-PAB;MC-Val-Cit-PAB/MC-VC-PAB-OH;Benzenemethanol,2-chloro-8-nitro-;MC-Val-Cit-PAB (ADC peptide linker)
- CBNumber:
- CB02554361
- Summenformel:
- C28H40N6O7
- Molgewicht:
- 572.65
- MOL-Datei:
- 159857-80-4.mol
|
MC-Val-Cit-PAB Eigenschaften
- Siedepunkt:
- 931.6±65.0 °C(Predicted)
- Dichte
- 1.276
- storage temp.
- under inert gas (nitrogen or Argon) at 2-8°C
- L?slichkeit
- DMSO: soluble
- Aggregatzustand
- powder to crystal
- pka
- 13.41±0.70(Predicted)
- Farbe
- White to Almost white
- InChIKey
- UMDCMQHPXQLHGR-OFVILXPXSA-N
- SMILES
- C(N)(=O)[C@H](CCCNC(N)=O)N(C(=O)[C@H](C(C)C)NC(=O)CCCCCN1C(=O)C=CC1=O)C1=CC=C(CO)C=C1
- CAS Datenbank
- 159857-80-4
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
|
Alarmwort |
Warnung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
|
|
Sicherheit |
P261 |
Einatmen von Staub vermeiden. |
P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
MC-Val-Cit-PAB Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide is used as a reagent to prepare antibody-drug conjugates, which are compounds that selectively deliver cytotoxic drugs to a tumour-associated antigen.
Application
MC-Val-Cit-PAB is a peptide linker that can be used to prepare antibody-drug conjugates (ADCs) for cancer therapy research. For example, CBP-1018, a dual-ligand PDC, is conjugated to MMAE via a cleavable linker (MC-Val-Cit-PABC) that can be cleaved by proteinase B
[1].
MC-Val-Cit-PAB can also be used to prepare cetuximab-vc-DOX-NPs conjugates, which have good tumor targeting ability and low systemic toxicity, and are a promising drug delivery targeting system
[2].
MC-Val-Cit-PAB Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
MC-Val-Cit-PAB Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 191)Lieferanten
- L-OrnithinaMide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aMinocarbonyl)-N-[4-(hydroxyMethyl)phenyl]-
- ML-Val-Cit-PAB
- MC-Val-Cit-PAB, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-
- MC-Val-Cit-PAB
- MC-Val-it-PAB
- N-[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-6-(2,5-dioxopyrrol-1-yl)hexanamide
- EOS-60616
- N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-(hydroxymeth
- N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N5-carbamoyl-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide
- 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-[(S)-1-[[(S)-1-[[4-(hydroxymethyl)phenyl]amino]-1-oxo-5-ureidopentan-2-yl]amino]-3-methyl-1-ox
- 6-(2,5-Dioxo-2,5-dihydro-1-pyrrolyl)-N-[(S)-1-[[(S)-1-[[4-(hydroxymethyl)phenyl]amino]-1-oxo-5-ureido-2-pentyl]amino]-3-methyl-1-oxo-2-butyl]hexanamide
- N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide
- 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide
- MC-Val-Cit-PAB-OH
- N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N5-carbamoyl-N2-[4-(hydroxymethyl)phenyl]-L-ornithinamide
- Benzenemethanol,2-chloro-8-nitro-
- MC-Val-Cit-PAB (ADC peptide linker)
- 6-(2,5-dioxopyrrol-1-yl)-N-[(1S)-1-[[(1S)-1-[[4-(hydroxymethyl)phenyl]carbamoyl]-4-ureido-butyl]carbamoyl]-2-methyl-propyl]hexanamide
- MC-Val-Cit-PAB/MC-VC-PAB-OH
- N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N5-carbamoyl-N2-[4-(hydroxymethyl)phenyl]-L-ornithinamide
- 159857-80-4
- 59857-80-4
- C28H40N6O7
- ADCs
- ADC Linker
- ADC-Linker
- ADC-Linkers